APRIL 2026 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA April 22. Tovorafenib – LGG BRAF. The European Commission (EC) has granted conditional marketing authorization for the Type II RAF kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade-glioma harbouring a BRAF fusion or rearrangement, […]